A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Birch in patients with allergic rhinitis/rhinoconjunctivitis caused by birch pollen

Trial Profile

A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Birch in patients with allergic rhinitis/rhinoconjunctivitis caused by birch pollen

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SUBLIVAC-FIX-Birch-DT-DRF
  • Most Recent Events

    • 03 Sep 2015 Results published in the Allergy.
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Status changed from recruiting to active, no longer recruiting according to HAL Allergy media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top